Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose randomized placebo-controlled study of QRL-101 in adults with amyotrophic lateral sclerosis
NL-OMON60141Phase 1Completed
- Sponsor
- QurAlis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing QRL-101 with Placebo (2 arms). Started Nov 2024; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON60141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60141.